Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness - PubMed
12 hours ago
- #DNA Damage Repair
- #Prostate Cancer
- #PARP Inhibitors
- Prostate cancers with DNA damage response and repair gene alterations are more aggressive and have poorer survival outcomes.
- PARP inhibitors (PARPi) improve survival in prostate cancer patients with BRCA1/2 mutations, but their efficacy in non-BRCA DNA repair gene alterations is still under investigation.
- The study reviews common genomic aberrations in DNA repair pathways in prostate cancer and emphasizes the need for better patient selection for PARPi treatment.
- Emerging treatments with novel DNA repair pathway inhibitors aim to address primary and secondary resistance challenges in prostate cancer.